NeurAxis, Inc.
- Market Cap (Float-Adj) (Float-adjusted market cap computed by the low-float screener — matches the screener row. May differ from the standard cap (price × all shares outstanding) reported elsewhere.)
- $87.3M
- Price
- $6.95
- % Change (Daily % change from the live per-ticker quote feed.)
- +2.51%
- Volume
- 61.6K
About
NeurAxis, Inc. (NRXS) is an American company specializing in neuromodulation therapy devices. Its primary offering is IB-Stim, a percutaneous electrical nerve field stimulation system engineered to alleviate functional abdominal pain associated with irritable bowel syndrome in patients aged 11 to 18. NeurAxis markets its solutions to healthcare providers, predominantly hospitals and clinics. The firm, headquartered in Carmel, Indiana, was established in 2011 and operated as Innovative Health Solutions, Inc. until its rebranding to NeurAxis, Inc. in March 2022.
Quick stats
Shares outstanding12.6M
Computed float8.7M
Float / shares69.5%
Key info
SectorHealthcare
IndustryBiotechnology
CIK (Central Index Key — the unique ID the SEC assigns to every filer. Use it to look up the company's filings on EDGAR.)0001933567
Websitehttps://neuraxis.com
AI Summary
AI-generated1/18
minorbullishexecutive change
NeurAxis Positions for Next Phase of Commercial Growth with Appointment of Craig Blanchard as Chief Commercial Officer
NeurAxis appointed Craig Blanchard as Chief Commercial Officer, overseeing sales and marketing as the company prepares to expand its commercial organization.
Blanchard previously led commercial strategy at NICO Corporation, whose technologies reached more than 40,000 patients before its 2024 acquisition by Stryker, and held commercial roles at Boston Scientific and Guidant.
Management frames the hire as preparing for a substantial increase in covered lives and broader physician adoption of IB-Stim, the company's FDA-cleared PENFS neuromodulation device for pediatric abdominal pain-related disorders.